Characteristic of KPC-12, a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in the Carbapenem-Resistant Klebsiella pneumoniae ST11-KL47 Clone Background
Weihua Han,Peiyao Zhou,Chun Chen,Chunyang Wu,Li Shen,Cailing Wan,Yanghua Xiao,Jiao Zhang,Bingjie Wang,Junhong Shi,Xinru Yuan,Haojin Gao,Hongxiu Wang,Ying Zhou,Fangyou Yu
DOI: https://doi.org/10.2147/idr.s465699
2024-06-21
Infection and Drug Resistance
Abstract:Weihua Han, 1, &ast Peiyao Zhou, 2, &ast Chun Chen, 3, &ast Chunyang Wu, 2 Li Shen, 1 Cailing Wan, 4 Yanghua Xiao, 4 Jiao Zhang, 2 Bingjie Wang, 1 Junhong Shi, 1 Xinru Yuan, 1 Haojin Gao, 1 Hongxiu Wang, 1 Ying Zhou, 1 Fangyou Yu 1 1 Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China; 2 Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China; 3 Cancer Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, People's Republic of China; 4 School of Public Health, Nanchang University, Nanchang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ying Zhou; Fangyou Yu, Email ; Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a great threat to public health worldwide. Ceftazidime-avibactam (CZA) is an effective β -lactam/ β -lactamase inhibitors against CRKP. However, reports of resistance to CZA, mainly caused by Klebsiella pneumoniae carbapenemase (KPC) variants, have increased in recent years. In this study, we aimed to describe the resistance characteristics of KPC-12, a novel KPC variant identified from a CZA resistant K. pneumoniae . Methods: The K. pneumoniae YFKP-97 collected from a patient with respiratory tract infection was performed whole-genome sequencing (WGS) on the Illumina NovaSeq 6000 platform. Genomic characteristics were analyzed using bioinformatics methods. Antimicrobial susceptibility testing was conducted by the broth microdilution method. Induction of resistant strain was carried out in vitro as previously described. The G. mellonella killing assay was used to evaluate the pathogenicity of strains, and the conjugation experiment was performed to evaluate plasmid transfer ability. Results: Strain YFKP-97 was a multidrug-resistant clinical ST11-KL47 K. pneumoniae confers high-level resistance to CZA (16/4 μg/mL). WGS revealed that a KPC variant, KPC-12, was carried by the IncFII (pHN7A8) plasmids (pYFKP-97_a and pYFKP-97_b) and showed significantly decreased activity against carbapenems. In addition, there was a dose-dependent effect of bla KPC-12 on its activity against ceftazidime. In vitro inducible resistance assay results demonstrated that the KPC-12 variant was more likely to confer resistance to CZA than the KPC-2 and KPC-3 variants. Discussion: Our study revealed that patients who was not treated with CZA are also possible to be infected with CZA-resistant strains harbored a novel KPC variant. Given that the transformant carrying bla KPC-12 was more likely to exhibit a CZA-resistance phenotype. Therefore, it is important to accurately identify the KPC variants as early as possible. Keywords: carbapenem-resistant Enterobacterales , Klebsiella pneumoniae , ceftazidime-avibactam, KPC-12, carbapenemase The global dissemination of carbapenem-resistant Enterobacterales (CRE) has emerged as an urgent public health concern due to extremely limited antibiotic treatment options. 1–3 Recognizing the significant threats posed by CRE, the World Health Organization has classified it as a priority antimicrobial resistant pathogen. It is worth mentioning that carbapenem-resistant Klebsiella pneumoniae strains (CRKP) account for over half of the clinical CRE infections in the United States, Europe and China, resulting in increased mortality rates. 4–6 Klebsiella pneumoniae , famous for its tendency to acquire multidrug resistance plasmids, is a notorious producer of Klebsiella pneumoniae carbapenemase (KPC)-type class A carbapenemases. The first KPC-positive K. pneumoniae strain was collected from the United States in the 1990s. 7 Shortly afterwards, the first KPC-producing K. pneumoniae strain reported in China was isolated from an ICU patient in Zhejiang Province in 2007. 8 With the increasing clinical use of carbapenems in recent decades, the prevalence of CRKP has also increased at an alarming rate. In China, approximately 60% of the CRKP strains produce KPC, with KPC-2 being the most prevalent carbapenemase. 9 Whereas, in the United States, Italy, and Israel KPC-3 is the predominant KPC-type carbapenemases.<su -Abstract Truncated-
pharmacology & pharmacy,infectious diseases